On August 16, the FDA issued an Emergency Use Authorization (EUA) for convalescent plasma as a treatment for COVID-19, finding that the known benefits of the treatment outweigh the known risks. The treatment takes antibody rich plasma and administers it to COVID patients to boost their immune response. The EUA does not replace the need for clinical trials and other safeguards for full FDA approval, but will make the treatment available to more patients.